Alkem Laboratories Limited
NSE:ALKEM.NS
5706.5 (INR) • At close November 8, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) INR.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 126,675.8 | 115,992.6 | 105,120.3 | 87,284 | 81,919.6 | 72,658.5 | 63,142.4 | 56,162.4 | 49,576.8 | 37,232.7 | 27,016.683 | 23,180.694 | 19,533.962 | 16,321.314 | 13,439.162 |
| Cost of Revenue
| 74,378.9 | 49,068.4 | 42,832.9 | 35,863.3 | 34,533.6 | 30,785 | 26,187.2 | 23,272.3 | 20,476.8 | 17,619.6 | 11,712.879 | 9,373.218 | 7,864.152 | 7,124.109 | 6,082.941 |
| Gross Profit
| 52,296.9 | 66,924.2 | 62,287.4 | 51,420.7 | 47,386 | 41,873.5 | 36,955.2 | 32,890.1 | 29,100 | 19,613.1 | 15,303.804 | 13,807.476 | 11,669.81 | 9,197.205 | 7,356.221 |
| Gross Profit Ratio
| 0.413 | 0.577 | 0.593 | 0.589 | 0.578 | 0.576 | 0.585 | 0.586 | 0.587 | 0.527 | 0.566 | 0.596 | 0.597 | 0.564 | 0.547 |
| Reseach & Development Expenses
| 5,229 | 5,411.4 | 5,690.4 | 5,336.5 | 4,739.5 | 4,635.1 | 3,646.2 | 3,203.7 | 2,165.5 | 1,695.5 | 1,569.6 | 1,081.7 | 0 | 0 | 0 |
| General & Administrative Expenses
| 19,541 | 2,991.4 | 2,475.8 | 2,226.8 | 1,691.3 | 1,699.4 | 1,277.3 | 1,361.7 | 1,306.9 | 917.9 | 660.192 | 478.646 | 294.538 | 136.61 | 113.521 |
| Selling & Marketing Expenses
| 8,065 | 13,150.8 | 10,490.3 | 6,836.3 | 8,368 | 7,130.4 | 6,741.6 | 5,807.5 | 5,334.5 | 4,137.5 | 3,430.481 | 2,793.746 | 2,253.18 | 1,711.352 | 1,474.532 |
| SG&A
| 27,606 | 16,142.2 | 12,966.1 | 9,063.1 | 10,059.3 | 8,829.8 | 8,018.9 | 7,169.2 | 6,641.4 | 5,055.4 | 4,090.673 | 3,272.392 | 2,547.718 | 1,847.962 | 1,588.053 |
| Other Expenses
| 3,108.4 | 2,160.8 | 251.2 | 63.8 | 31.9 | 95 | 118.9 | 20.8 | 47.6 | 57.1 | 103.978 | 32.949 | 5,331.908 | 6.209 | 6.193 |
| Operating Expenses
| 32,835 | 53,933.9 | 44,755.8 | 34,706.5 | 34,655.8 | 32,391.7 | 27,973 | 23,781.1 | 21,392.4 | 15,867.1 | 11,595.935 | 9,522.288 | 7,879.626 | 6,365.34 | 5,396.397 |
| Operating Income
| 19,461.9 | 13,195.9 | 17,432.1 | 16,739.3 | 12,660.2 | 9,417 | 8,982.2 | 9,109 | 7,707.6 | 3,746 | 3,707.869 | 4,285.188 | 3,790.184 | 2,831.865 | 1,959.824 |
| Operating Income Ratio
| 0.154 | 0.114 | 0.166 | 0.192 | 0.155 | 0.13 | 0.142 | 0.162 | 0.155 | 0.101 | 0.137 | 0.185 | 0.194 | 0.174 | 0.146 |
| Total Other Income Expenses Net
| 769.4 | -148.2 | 1,010.7 | 1,681.7 | -62.3 | 129.6 | 277.6 | 537.3 | 743.4 | 762.2 | 843.278 | 813.91 | 753.639 | 720.231 | 490.883 |
| Income Before Tax
| 20,231.3 | 13,047.7 | 18,442.8 | 18,421 | 12,597.9 | 9,546.6 | 9,259.8 | 9,646.3 | 8,451 | 4,508.2 | 4,551.147 | 5,099.098 | 4,543.823 | 3,552.096 | 2,450.707 |
| Income Before Tax Ratio
| 0.16 | 0.112 | 0.175 | 0.211 | 0.154 | 0.131 | 0.147 | 0.172 | 0.17 | 0.121 | 0.168 | 0.22 | 0.233 | 0.218 | 0.182 |
| Income Tax Expense
| 2,116.7 | 2,979.6 | 1,639.6 | 2,243.3 | 1,104.8 | 1,810.2 | 2,875.6 | 599.6 | 1,606 | 592.3 | 110.113 | 137.799 | 289.011 | 251.157 | 100.189 |
| Net Income
| 17,957.7 | 9,841.7 | 16,456.2 | 15,850.2 | 11,270.7 | 7,605.1 | 6,309.4 | 8,920.3 | 6,731.2 | 3,915.9 | 4,441.034 | 4,961.299 | 4,254.812 | 3,300.939 | 2,350.518 |
| Net Income Ratio
| 0.142 | 0.085 | 0.157 | 0.182 | 0.138 | 0.105 | 0.1 | 0.159 | 0.136 | 0.105 | 0.164 | 0.214 | 0.218 | 0.202 | 0.175 |
| EPS
| 150.19 | 82.31 | 137.63 | 132.57 | 94.26 | 63.61 | 52.77 | 74.61 | 62.02 | 32.75 | 36.71 | 41.49 | 35.58 | 27.05 | 19.66 |
| EPS Diluted
| 150.19 | 82.31 | 137.63 | 132.57 | 94.26 | 63.61 | 52.77 | 74.61 | 62.02 | 32.75 | 36.71 | 41.49 | 35.58 | 27.05 | 19.66 |
| EBITDA
| 22,454.9 | 18,255.3 | 21,917.4 | 20,782.9 | 15,859.5 | 12,003.9 | 11,439.6 | 11,066.6 | 10,150.4 | 5,993.3 | 5,823.224 | 6,233.849 | 5,239.644 | 3,814.721 | 2,691.055 |
| EBITDA Ratio
| 0.177 | 0.157 | 0.208 | 0.238 | 0.194 | 0.165 | 0.181 | 0.197 | 0.205 | 0.161 | 0.216 | 0.269 | 0.268 | 0.234 | 0.2 |